| Literature DB >> 33136300 |
Wilfried Mullens1,2, Angelo Auricchio3, Pieter Martens1,2, Klaus Witte4, Martin R Cowie5, Victoria Delgado6, Kenneth Dickstein7, Cecilia Linde8, Kevin Vernooy9,10, Francisco Leyva11, Johann Bauersachs12, Carsten W Israel13, Lars H Lund14, Erwan Donal15, Giuseppe Boriani16, Tiny Jaarsma17,18, Antonio Berruezo19, Vassil Traykov20, Zaheer Yousef21, Zbigniew Kalarus22, Jens Cosedis Nielsen23, Jan Steffel24, Panos Vardas25, Andrew Coats26, Petar Seferovic27, Thor Edvardsen28, Hein Heidbuchel29, Frank Ruschitzka30, Christophe Leclercq15.
Abstract
Cardiac resynchronization therapy (CRT) is one of the most effective therapies for heart failure with reduced ejection fraction and leads to improved quality of life, reductions in heart failure hospitalization rates and all-cause mortality. Nevertheless, up to two-thirds of eligible patients are not referred for CRT. Furthermore, post-implantation follow-up is often fragmented and suboptimal, hampering the potential maximal treatment effect. This joint position statement from three European Society of Cardiology Associations, Heart Failure Association (HFA), European Heart Rhythm Association (EHRA) and European Association of Cardiovascular Imaging (EACVI), focuses on optimized implementation of CRT. We offer theoretical and practical strategies to achieve more comprehensive CRT referral and post-procedural care by focusing on four actionable domains: (i) overcoming CRT under-utilization, (ii) better understanding of pre-implant characteristics, (iii) abandoning the term 'non-response' and replacing this by the concept of disease modification, and (iv) implementing a dedicated post-implant CRT care pathway. © the Author(s) 2020. This article has been co-published with permission in European Journal of Heart Failure (published by John Wiley & Sons Ltd on behalf of European Society of Cardiology) and EP Europace.Entities:
Keywords: Cardiac resynchronization therapy; Care pathways; Disease management; Disease modification; Heart failure; Implementation; Outcome; Response; Utilization
Mesh:
Year: 2020 PMID: 33136300 DOI: 10.1002/ejhf.2046
Source DB: PubMed Journal: Eur J Heart Fail ISSN: 1388-9842 Impact factor: 15.534